Cancer

June 17, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SMARCA4, KIBRA, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 17/June/2019, 5.48 am

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]
June 13, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 13/June/2019, 10.26 pm

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]
June 9, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TIMP3, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 09/June/2019, 6.23 pm

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]
June 5, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 05/June/2019, `7.17 am

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]